SOW
XENE icon

State of Wyoming’s Xenon Pharmaceuticals XENE Stock Holding History

State of Wyoming’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$526K Buy
8,710
+7,329
+531% +$407K 0.05% 374
2026
Q1 		$80.3K Sell
1,381
-120
-8% -$5.53K 0.01% 1348
2025
Q4 		$67.3K Buy
1,501
+350
+30% +$14.7K 0.01% 1453
2025
Q3 		$46.2K Buy
1,151
+610
+113% +$21.5K 0.01% 1598
2025
Q2 		$16.9K Sell
541
-33
-6% -$1.08K ﹤0.01% 1727
2025
Q1 		$19.3K Buy
574
+30
+6% +$1.14K ﹤0.01% 1564
2024
Q4 		$21.3K Hold
544
– – ﹤0.01% 1520
2024
Q3 		$21.4K Buy
544
+250
+85% +$10.1K ﹤0.01% 1588
2024
Q2 		$11.5K Sell
294
-6
-2% -$240 ﹤0.01% 1569
2024
Q1 		$12.9K Buy
+300
New +$13.8K ﹤0.01% 1546
2022
Q3 		– Sell
-64
Closed -$2K – 1982
2022
Q2 		$2K Buy
64
+15
+31% +$454 ﹤0.01% 1793
2022
Q1 		$1K Buy
49
+9
+23% +$269 ﹤0.01% 1751
2021
Q4 		$1K Sell
40
-2
-5% -$60 ﹤0.01% 1830
2021
Q3 		$1K Sell
42
-22
-34% -$382 ﹤0.01% 1194
2021
Q2 		$1K Buy
+64
New +$1.18K ﹤0.01% 1149

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

State of Wyoming's XENE Position: Q2 2026 in Review

State of Wyoming increased its Xenon Pharmaceuticals (XENE) stake by 531% in Q2 2026, buying an estimated $407K and bringing the position to 8,710 shares worth $526K. The position accounts for 0.05% of the portfolio, ranked #374.

State of Wyoming first reported a position in XENE in Q2 2021 and has held it in 15 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • State of Wyoming held 8,710 shares of Xenon Pharmaceuticals worth $526K as of Q2 2026.
  • State of Wyoming bought 7,329 Xenon Pharmaceuticals shares in Q2 2026, an estimated $407K.
  • Xenon Pharmaceuticals made up 0.05% of State of Wyoming's portfolio in Q2 2026, its #374 holding.
  • State of Wyoming first reported a position in Xenon Pharmaceuticals in Q2 2021 and has held it in 15 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on State of Wyoming's 13F filing for Q2 2026, filed 6 Aug 2026.